Form 4 for PCSA Processa Pharmaceuticals, Inc.
Accepted 2024-01-31 00:00:00 ET · period of report 2024-01-30 · accession 0000897069-24-000229 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-01-31 | 2024-01-30 | PCSA | Ng George K | CEO, Dir | P - Purchase | $2.70 | +10.0K | 20.0K | +100% | +$27.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-30 | P | A | 10,000 | $2.70 | 20,000 | I By Family Trust | — | — | (F1) Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. (F2) Reflects that shares previously reported as directly held by the reporting person were held in a trust. |